Antibody-Drug Conjugates as Radiopharmaceutical Theranostics for Cancer
This grant opportunity supports the development of an innovative treatment approach using antibody-drug conjugates (ADCs) combined with radionuclides for cancer therapy. The project aims to overcome the limitations of ADCs, such as cancer resistance and ineffective drug delivery, by adding radionuclides that enable diagnostic imaging and enhance therapeutic effects. The use of diagnostic radio…
Source
Dates
Program & Phase
Keywords
Supporting Links
Documents
Similar Opportunities
-
Radiopharmaceuticals for WBAMC
Department of the Army
-
Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
National Institutes of Health
-
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
National Institutes of Health
-
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
National Institutes of Health
-
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
National Institutes of Health
Find tens of thousands more opportunities — free
Scout accounts are free. Sign up to browse the full funding database, unlock the solicitation links and documents for this opportunity, and see how well each one fits your organization.
-
Tens of thousands of funding opportunities
Search and filter every grant and solicitation in Scout — all free, no credit card required.
-
Instant Fit Analysis
Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
-
Source links & full documents
Jump straight to the solicitation and download every attachment.
-
Save opportunities & track deadlines
Keep the opportunities that fit in one place and stay ahead of every due date.
Already have an account? Sign In
Trusted by 500+ Happy Customers